Reduction of vasoconstriction mediated by neuropeptide Y Y2 receptors in arterioles of the guinea-pig small intestine

Heterogeneous control of blood flow amongst different vascular beds

The control and maintenance of vascular tone is due to a balance between vasoconstrictor and vasodilator pathways. Vasomotor responses to neural, metabolic and physical factors vary between vessels in different vascular beds, as well as along the same bed, particularly as vessels become smaller. These differences result from variation in the composition of neurotransmitters released by perivascular nerves, variation in the array and activation of receptor subtypes expressed in different vascular beds and variation in the signal transduction pathways activated in either the vascular smooth muscle or endothelial cells. As the study of vasomotor responses often requires pre-existing tone, some of the reported heterogeneity in the relative contributions of different vasodilator mechanisms may be compounded by different experimental conditions. Biochemical variations, such as the expression of ion channels, connexin subtypes and other important components of second messenger cascades, have been documented in the smooth muscle and endothelial cells in different parts of the body. Anatomical variations, in the presence and prevalence of gap junctions between smooth muscle cells, between endothelial cells and at myoendothelial gap junctions, between the two cell layers, have also been described. These factors will contribute further to the heterogeneity in local and conducted responses.

Signaling mechanisms underlying the vascular myogenic response

The vascular myogenic response refers to the acute reaction of a blood vessel to a change in transmural pressure. This response is critically important for the development of resting vascular tone, upon which other control mechanisms exert vasodilator and vasoconstrictor influences. The purpose of this review is to summarize and synthesize information regarding the cellular mechanism(s) underlying the myogenic response in blood vessels, with particular emphasis on arterioles. When necessary, experiments performed on larger blood vessels, visceral smooth muscle, and even striated muscle are cited. Mechanical aspects of myogenic behavior are discussed first, followed by electromechanical coupling mechanisms. Next, mechanotransduction by membrane-bound enzymes and involvement of second messengers, including calcium, are discussed. After this, the roles of the extracellular matrix, integrins, and the smooth muscle cytoskeleton are reviewed, with emphasis on short-term signaling mechanisms. Finally, suggestions are offered for possible future studies.

Expression of neuropeptide Y receptors mRNA and protein in human brain vessels and cerebromicrovascular cells in culture

Neuropeptide Y (NPY) has been suggested as an important regulator of CBF. However, except for the presence of Y1 receptors in large cerebral arteries, little is known about its possible sites of action on brain vessels. In this study, we sought to identify the NPY receptors present in the human cerebrovascular bed. Specific Y1 receptor binding sites, localized on the smooth muscle of human pial vessels and potently competed by NPY, polypeptide YY (PYY), and the selective Y1 receptor antagonist BIBP 3226, were identified by quantitative radioautography of the Y1 radioligand [125I]-[Leu31, Pro34]-PYY. In contrast, no specific binding of the Y2-([125I]-PYY3-36) and Y4/Y5-(125I-human pancreatic polypeptide [hPP]) radioligands could be detected. By in situ hybridization, expression of Y1 receptor mRNA was restricted to the smooth muscle layer of pial vessels, whereas no specific signals were detected for either Y2, Y4, or Y5 receptors. Similarly, using reverse transcriptase-polymerase chain reaction (RT-PCR), mRNA for Y1 but not Y2, Y4, or Y5 receptors was consistently detected in isolated human pial vessels, intracortical microvessels, and capillaries. In human brain microvascular cells in culture, PCR products for the Y1 receptors were exclusively found in the smooth muscle cells. In cultures of human brain astrocytes, a cell type that associates intimately with brain microvessels, PCR products for Y1, Y2, and Y4 but not Y5 receptors were identified. Finally, NPY significantly inhibited the forskolin-induced cAMP production in smooth muscle but not in endothelial cell cultures. We conclude that smooth muscle Y1 receptors are the primary if not exclusive NPY receptors associated with human brain extraparenchymal and intraparenchymal blood vessels, where they most likely mediate cerebral vasoconstriction.

Neuropeptide Y and Y1-receptor agonists increase blood flow through arteriovenous anastomoses in rat tail

The purpose of this study was to characterize neuropeptide Y (NPY)-induced vasodilation in the rat tail. Sterile surgical technique was used (with pentobarbital sodium anesthesia) to equip rats with a jugular catheter and a blind-ended thermocouple reentrant tube next to the carotid artery. Tail skin and core temperature were measured with thermocouples during experiments. Tail skin blood flow was monitored with a laser Doppler flowmeter, and tail total blood flow and volume were measured with plethysmography. After baseline data were collected, saline, NPY (16, 32, 64, and 128 microg/kg), [Leu31 Pro34]NPY (63.25 microg/kg), or NPY[13-36] (44.7 microg/kg) was administered intravenously. Tail total blood flow, volume, and tail skin temperature increased, whereas tail skin blood flow and core temperature decreased in response to both NPY- and the Y1-receptor agonist [Leu31 Pro34]NPY but not in response to saline or NPY[13-36]. Studies conducted with the use of color microspheres demonstrated that arteriovenous anastomoses are involved in this NPY-induced vasodilation.

Modulation of submucosal arteriolar tone by neuropeptide Y Y2 receptors in the guinea-pig small intestine

OBJECTIVES

the aims of this study were to determine if the nerves, both intrinsic and extrinsic, supplying intestinal blood vessels were subject to modulation by a neuropeptide Y2 receptor agonist, N-acetyl[Leu28, Leu31] NPY(24-36).

METHODS

effects of Y2 receptor agonist were examined on (i) responses to acetylcholine (ACh) and intrinsic vasodilator nerve stimulation in normal arterioles and (ii) amplitudes of arteriolar constrictions and smooth muscle membrane potential changes in response to extrinsic perivascular nerve stimulation in both normal and capsaicin-treated arterioles.

RESULTS

(i) neuropeptide Y2 receptor agonist had no significant effect on the relaxing action of exogenous application of ACh but significantly reduced the relaxing action of vasodilator nerve stimulation in arterioles of the isolated submucosa of the guinea-pig small intestine, which were pre-constricted with the thromboxane analogue U46619. (ii) The Y2 agonist significantly decreased the amplitude of excitatory junction potentials (EJPs) evoked by perivascular nerve stimulation in normal arterioles and in arterioles treated with the sensory neurotoxin, capsaicin. On the other hand, the Y2 agonist failed to alter the amplitude of the constrictions obtained by perivascular nerve stimulation in normal arterioles but significantly attenuated the amplitude of constrictions in arterioles treated with capsaicin.

CONCLUSIONS

it is concluded that NPY can modulate release of transmitter from extrinsic sympathetic as well as the intrinsic submucosal vasodilator nerves via prejunctional Y2 receptors.

Neuropeptide Y Y1 receptors in vascular pharmacology

The existence of neurogenic mediator candidates apart from noradrenaline and acetylcholine involved in the control of vascular tone has attracted enormous attention during the past few decades. One such mediator is neuropeptide Y (NPY), which is co-localized with noradrenaline in sympathetic perivascular nerves. Stimulation of sympathetic nerves in vitro and in vivo causes non-adrenergic vasoconstriction which can be blocked by experimental manipulations that inhibit NPY mechanisms. Thus, the vasopressor response to stimulation of sympathetic nerves can be attenuated by chemical or surgical sympathectomy, treatment with reserpine or other pharmacological agents, and tachyphylaxis to NPY or by NPY antagonists. The NPY field was long plagued by a lack of specific antagonists, but with the recently developed, selective, non-peptide and stable NPY antagonists it has now become possible to study subtypes of this receptor family. For instance, it has become clear that the NPY Y1 receptor mediates most of the direct peripheral effects of NPY on vascular tone. These antagonists promise to stimulate NPY research and will likely unravel the true significance of NPY in cardiovascular control under physiological conditions as well as in pathophysiological states.

A role for neuropeptide Y in rat iridial arterioles

A role for neuropeptide Y (NPY) in neurotransmission in rat iridial arterioles has been investigated. Reverse transcription-polymerase chain reaction analysis has demonstrated mRNA expression for both Y1 and Y2 receptors in the superior cervical ganglion and iris. The Y1 agonist [Leu31,Pro34]NPY caused a dose-dependent constriction of iris arterioles (50% effective concentration of 10(-8) M), but, at low concentrations (10(-9) and 10(-10) M), it failed to potentiate either submaximal responses to norepinephrine (10(-6) M) or submaximal, noradrenergic responses to nerve stimulation. In contrast, 10(-7) M [Leu31,Pro34]NPY potentiated submaximal, noradrenergic responses to nerve stimulation (10 Hz, < or = 1 s) and to a concentration of norepinephrine (10(-7) M) which produced only small contractions. The Y1 antagonist 1229U91 blocked contractions induced by [Leu31,Pro34]NPY. Stimulation of the nerves for longer periods (10 or 20 Hz; 5, 30, or 60 s) revealed a component of the response which was reduced by 1229U91. This component was not apparent after brief stimuli (10 Hz, < or = 1 s), even when opposing receptor pathways were blocked. The Y2 agonist N-acetyl-[Leu28,Leu31]NPY24-36 had little effect on arterioles preconstricted with either high potassium or an alpha 2-adrenoceptor agonist, or on nerve-mediated contractions. Results suggest that NPY, released from sympathetic nerves during long-duration, high-frequency stimulation, activates Y1 receptors on iris arterioles to produce vasoconstriction and to potentiate responses to low concentrations of norepinephrine.

Conducted depolarization in arteriole networks of the guinea-pig small intestine: effect of branching of signal dissipation

1. Blood flow control requires co-ordinated activity among many branches of arteriole networks, which may be achieved by conduction of membrane potential changes between arteriolar smooth muscle cells and endothelial cells. 2. We investigated the effect of branching upon the passive conduction of electrical signals through the syncytium of electrically coupled cells in arteriole networks (n = 12) prepared from the guinea-pig submucosa. To describe the effect of branching on cable properties, the expansion parameter B was calculated (B = 1 for an unbranched cable; B > 1 with branching) for a point in each arteriole network based on anatomy. 3. An estimate of B(B') was also obtained by measuring the spread of depolarization caused by a high-K+ stimulus applied to one region. Membrane potential (-74 +/- 4 mV (+/- S.D.) at rest) was recorded from smooth muscle cells (verified with intracellular dye labelling). A micropipette containing 120 mM KCl was positioned at 150 micron increments along an arteriole (width, 50-75 microns) up to approximately 1.2 mm from a stationary recording site, producing stable depolarization which decreased as separation distance increased. The dissipation of depolarization with separation was greater when recording near branch origins rather than continuous segments. 4. B ranged in value from 0.99 to 2.28. In any one experiment, values of B and B' were correlated (correlation coefficient, r = 0.71; P < 0.05), but B' was consistently greater than B, and we discuss methodological factors which could lead to erroneously high values for B'. 5. For pooled electrophysiological data, depolarization decayed to 37% (1/e) of initial values in approximately 700 microns, consistent with B > 1. In contrast, the conduction of vasoconstriction and vasodilatation exceeds 2 mm in arteriole networks in previous studies. To explain this discrepancy, we suggest that active electrical events in cells of the arteriole wall augment passive electrical conduction during blood flow control.

Neuropeptide Y is a vasoconstrictor and adrenergic modulator in the hamster microcirculation by acting on neuropeptide Y1 and Y2 receptors

The microvascular effects of neuropeptide Y, and two analogs with preferential affinity for different neuropeptide Y receptor subtypes, were assessed by intravital microscopy on the hamster cheek pouch. The interaction of neuropeptide Y and its analogs with noradrenaline was also studied. Superfusion with 0.1-300 nM neuropeptide Y caused a concentration-dependent reduction in microvascular conductance that was paralleled by reductions in arteriolar and venular diameters. These effects of neuropeptide Y were equipotent with noradrenaline, but slower to develop and longer-lasting than that of noradrenaline. Neuropeptide Y did not affect permeability to macromolecules, as measured by extravasation of fluorescent dextran. The neuropeptide Y Y1 receptor agonist, [Leu31,Pro34]neuropeptide Y, mimicked neuropeptide Y with similar potency but shorter duration, while neuropeptide Y-(13-36), a neuropeptide Y Y2 receptor agonist, was at least 10-fold less potent than neuropeptide Y to induce a delayed and prolonged reduction in microvascular conductance. The joint superfusion of 1 nM neuropeptide Y plus 0.1 mu M noradrenaline did not cause synergism, nor even summation of effects, but reduced the contractile effect of noradrenaline. No synergism was observed after a 10 min priming with 1 nM neuropeptide Y, followed by its joint application with 0.1 mu M noradrenaline, but a significant vasodilation and hyperemia ensued upon stopping noradrenaline application. Priming with 1 nM [Leu31,Pro34]neuropeptide Y prolonged noradrenaline vasoconstriction without evidence of hyperemia. In contrast, priming with 1 nM neuropeptide Y-(13-36) significantly antagonized noradrenaline vasoconstriction. These findings indicate that both neuropeptide Y receptor subtypes are present in arterioles and venules of the hamster, and suggest that their activation with neuropeptide Y induces a rapid (Y1 receptor subtype activation) and a delayed (Y2 receptor subtype activation) vasocontractile response. The interaction with noradrenaline is complex, without evidence for synergism, but neuropeptide Y Y2 receptor activation seems to antagonize noradrenaline and/or to facilitate auto-regulatory vasodilation after the catecholamine-induced vasoconstriction.